Viewing Study NCT01977651

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:54 PM
Ignite Modification Date: 2026-03-11 @ 4:36 PM
Study NCT ID: NCT01977651
Status: COMPLETED
Last Update Posted: 2024-12-06
First Post: 2013-10-31
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide
Sponsor: Astellas Pharma Global Development, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Castration-resistant Prostate Cancer (mCRPC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None enzalutamide View
None Xtandi View
None seizure View
None Central Nervous System View
None MDV3100 View
None metastatic castration-resistant prostate cancer (mCRPC) View